News | April 29, 1999

ENDOCARE RECEIVES CE MARK FOR HORIZON PROSTATIC STENT

IRVINE, Calif., April 29 /PRNewswire/ -- Endocare, Inc. (Nasdaq: ENDO) announced today that it has received CE Mark for its prostatic nitinol stent allowing the Company to sell the product in all countries of the European Union and the European Free Trade Area.

BPH, or enlarged prostate, is a non-cancerous growth of prostate tissue that obstructs bladder function causing discomfort and lifestyle complications for afflicted men. The estimate of men worldwide displaying symptoms of BPH approach over 20 million. The Horizon Prostatic Stent is designed to provide immediate relief for prostate obstruction with quick and easy introduction and removal through a minimally invasive procedure.

"With CE Mark Certification, we are now positioned to begin our initial commercialization of the Horizon Prostatic Stent in Europe. This is an important step in providing an advanced stent technology to medical professionals in the European Union and opens up significant market opportunities for this product," said Paul W. Mikus, chief executive officer of Endocare. The Company is currently in discussions with a number of distributors to market and sell the Horizon Prostatic Stent in Europe and various countries outside the United States.

CE marking is an internationally recognized European symbol of conformance to strict standards of product quality and safety. In January 1999, the Company received CE Mark for its Targeted CryoAblation Technology and was granted ISO 9001 Certification of its Quality System. Mikus added, "Obtaining CE Mark Certification for our stent is a tribute to Endocare's dedication and focused efforts toward quality."

Endocare (www.ecare.org) develops, manufactures, and markets an array of innovative, temperature-based surgical devices and technologies, including those used in targeted cryoablation for treatment of prostate cancer. The company is also developing other innovative prostatic stent technologies.

Any statements in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Actual results may differ from those indicated by forward-looking statements as a result of a variety of factors, including competitive developments, regulatory approval requirements, and the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products. These and other factors that could materially and adversely impact revenues and profitability are detailed from time to time in the Company's periodic reports, including Quarterly Reports on Form 10-Q, the Annual Report on Form 10-K and the Registration Statement on Form S-3, filed with the Securities and Exchange Commissions. The Company undertakes no obligation to update forward-looking statements. SOURCE Endocare, Inc.

-0-                             04/29/99 /CONTACT:  Paul Williams for 
Endocare, Inc., 310-937-2009/ 

/Web site: http://www.ecare.org/ (ENDO)
CO: Endocare, Inc. ST: California IN: MTC HEA SU: PDT